Can Anti-TNFα Antibodies Affect SARS-CoV-2 Disease Outcomes? (original) (raw)

This letter discusses the potential effects of anti-TNFα antibodies, specifically infliximab, on COVID-19 outcomes. The systemic inflammatory response triggered by SARS-CoV-2 leads to high levels of TNFα in severe cases, and preliminary observations suggest that infliximab treatment can reduce inflammatory markers and improve clinical outcomes in severely infected patients. The conclusion highlights the need for further clinical trials to assess the efficacy of anti-TNFα therapy in managing SARS-CoV-2 infections.